Clinical Efficacy of Tegafur Gimeracil Oteracil Potassium Capsule Plus Paclitaxel in Treatment of Advanced Gastric Cancer / 医学研究杂志

ABSTRACT

Objective To assess and analyze the efficacy and safety of Tegafur Gimeracil Oteracil Potassium capsule plus paclitaxel against advanced gastric cancer. Methods Totally 61 patients with advanced gastric cancer were randomly divided into two groups the treatment group(32 cases) and the control group(29 cases). Patients in the treatment group were treated with Tegafur Gimeracil Oteracil Potassium capsule (80mg /m2 ) orally, for 14 days continuously, and paclitaxel (175mg/m2 ) on the first day. Patients in the control group were applied with oxaliplatin (130mg/m2 ) on the first day, and the same dose of Tegafur Gimeracil Oteracil Potassium capsule. The two groups both used three weeks as a cycle. Results All 61 patients were included for analysis. No complete response was ob-served. The overall disease control rate was 84. 4%, 79. 3%, respectively. The median progression free survival time was respectively 5. 6 months and 4. 9 months. The median survival time was respectively 13. 1 months and 13. 6 months. There's no significant difference between the two groups. The adverse effects were mostly tolerable, big part of which grade 1/2, mainly included hematological adverse effects, digestive system adverse effect, fatigue and so on. The incidence of neurotoxic effect of control group was higher than treatment group. Conclusion Tri-weekly paclitaxel combined Tegafur Gimeracil Oteracil Potassium Capsule is safe and effective in patients with advanced gastric cancer, which is worthy further study.